On May 26, 2023 Takeda (TSE: 4502/NYSE:TAK) reported that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), June 8-11, 2023, in Frankfurt, Germany (Press release, Takeda, MAY 26, 2023, View Source [SID1234632161]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company’s presence at ASCO (Free ASCO Whitepaper) 2023 will underscore Takeda’s growing solid tumor portfolio, with research focused on improving treatment for metastatic colorectal cancer (CRC), as well as rare forms of oncogene-driven non-small cell lung cancer (NSCLC). Within its hematology portfolio, Takeda will present data in oral sessions at both ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) on a head-to-head Phase 3 study comparing targeted treatments in newly diagnosed patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
"Over the past year, we have made significant advancements with our pipeline – both in progress with our innate immunity enhancers and in further diversifying our pipeline – aiming to ultimately deliver transformative medicines to patients who need them most," said Awny Farajallah, M.D., head, global medical affairs, oncology at Takeda. "With our aspiration to cure cancer in mind, we are excited to share data from our newly expanded solid tumor portfolio featuring results in colorectal cancer, as well as research from our established hematological portfolio where we continue to explore the potential for a new standard of care treatment in acute lymphoblastic leukemia."
A full list of company-sponsored abstracts are available for ASCO (Free ASCO Whitepaper) (here) and EHA (Free EHA Whitepaper) (here).